evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,918 questions · 5,537 findings · 1,803 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1,309 · 23.6%GRADE not reported 440 · 7.9%Very low 1,560 · 28.2%Low 1,292 · 23.3%Moderate 751 · 13.6%High 185 · 3.3%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Persea gratissma + Glycine max (ASU 300 mg) vs chondroitin sulphate

Adverse events Participants (n) reported serious adverse events · patients with osteoarthritis

Persea gratissma + Glycine max (ASU 300 mg) showed no clear difference in adverse events Participants (n) reported serious adverse events compared with chondroitin sulphate (low certainty).

1 finding from 1 review

Psychological interventions vs usual care

Treatment‐related adverse events Depression PHQ‐8 (Kroenke 2009) · children, adolescents or adults with CF

Summary of findings: psychological interventions showed no clear difference in treatment‐related adverse events Depression PHQ‐8 (Kroenke 2009) compared with usual care (low certainty).

1 finding from 1 review

Mepolizumab intravenous (IV) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Mepolizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Reslizumab intravenous (IV) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Reslizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Reslizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Reslizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Benralizumab subcutaneous (SC) leads to higher clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Mepolizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Mepolizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Donepezil 5 mg vs placebo

Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

PFMT added to continence pessary vs pelvic floor muscle training (PFMT)

Number of women with adverse events ‐ de novo voiding difficulty · pelvic organ prolapse in women

Pessary plus PFMT showed no clear difference in number of women with adverse events ‐ de novo voiding difficulty compared with pelvic floor muscle training (PFMT) alone (low certainty).

1 finding from 1 review

Sublingual immunotherapy vs control

All adverse events Weighted mean duration of studies: 60 weeks** · people with asthma

Sublingual immunotherapy leads to higher all adverse events Weighted mean duration of studies: 62 weeks** compared with control (high certainty).

1 finding from 1 review

Intervention not reported

Adverse events (serious ‐ resulting in hospitalisation or death) · adults aged ≥ 18 years with a diagnosis of glenohumeral osteoarthritis who have not responded to non‐operative treatments
1 finding from 1 review

Acupuncture vs no intervention

Proportion of participants with 1 or more serious adverse events · chronic hepatitis B

The review found no eligible studies for this question.

1 finding from 1 review

Intervention vs no intervention or control intervention (control)

Adverse events (number) ‐ interferon‐beta versus no intervention · people with acute hepatitis C infection

It is very uncertain whether intervention changes adverse events (proportion) ‐ interferon‐beta versus no intervention compared with no intervention or control intervention (control) (very low certainty).

2 findings from 1 review

Terlipressin vs other vasoactive drugs

Non‐serious adverse events: diarrhoea or abdominal pain, or both · people with cirrhosis and hepatorenal syndrome

It is very uncertain whether terlipressin changes non‐serious adverse events: diarrhoea or abdominal pain, or both compared with other vasoactive drugs (very low certainty).

1 finding from 1 review

RISPERIDONE DEPOT vs ARIPIPRAZOLE

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL ARIPIPRAZOLE (very low certainty).

1 finding from 1 review